Gilead Sciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GILD | BMY | BIIB | NOT.F | SNY | GSK | |
|---|---|---|---|---|---|---|
| Market cap | 216.41B | 131.21B | 37.61B | 274.68B | 113.74B | 102.53B |
| P/E (TTM) | — | 14.2 | 110.2 | 32.2 | 23.6 | 17.8 |
| Forward P/E | 17.3 | 9.6 | 15.6 | — | 8.9 | 10.3 |
| Price/book | 16.6 | 5.6 | 2.0 | 8.3 | 1.4 | 4.1 |
| Dividend yield | 1.88% | 3.93% | — | 2.85% | 5.10% | 3.55% |
| 1-year change | +41.39% | +37.66% | +62.35% | +32.38% | −4.08% | +8.60% |
| Today | +4.19% | +4.02% | +2.22% | +0.43% | +4.72% | +5.03% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All GILD news ›What Could Go Wrong At Gilead From Here?
Gilead Faces A Lower Medicare Price For Biktarvy CMS sets the Medicare price for Biktarvy, Gilead’s largest product. During its October 29, 2026 earnings call, management said the agency set the drug’s Medicare price at $2,600 per 30-day…
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Nov 4, 2026 9:15am EST – iMMagine-1 Data Provide 18 Months Minimum Follow-Up on Anito-cel’s Durability and Safety in Relapsed or Refractory Multiple Myeloma – – Five-Year ZUMA-12 Follow-Up Data to Provide Long-Term Evidence for Yescarta®…
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise - This is the…
Arcus Biosciences Q3 revenue drops on lower Gilead collaboration
TradingView Arcus Biosciences Q3 revenue drops on lower Gilead collaboration
Dr. Reddy's granted FDA nod for first generic targeting Gilead’s Yeztugo
Dr. Reddy's generic targeting Gilead’s Yeztugo approved (GILD) Seeking Alpha - Dr. Reddy's Laboratories (RDY) has become the first drugmaker to receive U.S. approval for a generic targeting Yeztugo, a twice-yearly HIV preventative medicine…
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that…
Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.
Get Our Latest Research Report on GILD The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share.…
Gilead Sciences, Inc. $GILD Stock Purchased by Provenance Wealth Advisors LLC
GILD stock opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The firm has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The business's 50 day moving…
Gilead Sciences, Inc. $GILD Stock Acquired by Aware Super Pty Ltd as trustee of Aware Super
Check Out Our Latest Analysis on GILD GILD stock opened at $167.47 on Wednesday. The firm has a 50 day moving average price of $151.77 and a 200-day moving average price of $140.25. Gilead Sciences, Inc. has a 52-week low of $116.88 and a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com42
- marketbeat.com25
- seekingalpha.com14
- stocktitan.net10
- tradingview.com10
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.